Alnylam Pharmaceuticals Inc

ALNY

$131.30

-9.1% (1 year change)

Avg closing price

Price range

Market Cap

$15.5 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$119.29 - $178.41

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

-17.72x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $15.5 Billion
Enterprise Value $13.8 Billion
Dividend Yield $0.00 (0.0%)
1 Year Return -9.1%
52-Week High $178.41
52-Week Low $119.29
Beta 0.81
Outstanding Shares 118 Million
Avg 30 Day Volume 512 Thousand

Valuation

P/E Ratio -17.72
PEG 149.9
Earnings per Share -$7.55
Price to Sales Ratio 43.77
Price to Book Ratio 16.41
Revenue to Enterprise Value 31.56
EBIT to Enterprise Value -15.36
Total Debt to Enterprise Value 0.01
Debt to Equity 0.19

Profitability

Revenue $439 Million
Gross Profit $370 Million
EBIT -$901 Million
Net Income -$881 Million
Profit Margin -200.87%
Quarterly Earnings Growth (YoY) -11.8%
Return on Equity -86.71%
Return on Assets -25.86%
Return on Invested Capital -31.94%

News

Alnylam to Webcast Presentation at 10th Annual SVB Leerink Global Healthcare Conference

Alnylam to Webcast Presentation at 10th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 10th A...

Business Wire Business Wire, 3 months ago
Chardan Capital Stick to Their Buy Rating for Alnylam Pharmaceuticals By Investing.com

Chardan Capital Stick to Their Buy Rating for Alnylam Pharmaceuticals By Investing.com

Chardan Capital Stick to Their Buy Rating for Alnylam Pharmaceuticals

Investing.com Investing.com, 3 months ago
Oppenheimer Stick to Their Hold Rating for Alnylam Pharmaceuticals By Investing.com

Oppenheimer Stick to Their Hold Rating for Alnylam Pharmaceuticals By Investing.com

Oppenheimer Stick to Their Hold Rating for Alnylam Pharmaceuticals

Investing.com Investing.com, 3 months ago